Concepedia

Henry T. Quach

HT

Statistics

Publications

10

Citations

954

H-Index

10

Active since

2019

Affiliations

Vanderbilt University Medical Center(Current)

Vanderbilt University

University of Alabama at Birmingham

Memorial Sloan Kettering Cancer Center

Shanxi Academy of Medical Sciences

Henry T. Quach is an author at Vanderbilt University Medical Center specializing in oncology, cancer immunotherapy, and immunotherapy.

ORCID

Publications per year

2019–2022

10

Publications

10

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study

Douglas B. Johnson, Ali Manouchehri, Alexandra M. Haugh et al. · Journal for ImmunoTherapy of Cancer · 2019 · 356 citations · Full text

, , +17

Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti–PD-1 Monotherapy

Xue Bai, Jiani Hu, Allison Betof Warner et al. · Clinical Cancer Research · 2021 · 176 citations · Full text

, , +17

Association of Anti–Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma

Henry T. Quach, Anna K. Dewan, Elizabeth J. Davis et al. · JAMA Oncology · 2019 · 109 citations · Full text

, , +17

Impact of body composition on outcomes from anti-PD1 +/− anti-CTLA-4 treatment in melanoma

Arissa Young, Henry T. Quach, Haocan Song et al. · Journal for ImmunoTherapy of Cancer · 2020 · 101 citations · Full text

, , +17

Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand

James R. Patrinely, Arissa Young, Henry T. Quach et al. · European Journal of Cancer · 2020 · 59 citations · Full text

, , +17

1–5 of 10